Cargando…
Repurposing drugs to target nonalcoholic steatohepatitis
Nonalcoholic fatty liver disease (NAFLD) is a complex disorder that has evolved in recent years as the leading global cause of chronic liver damage. The main obstacle to better disease management pertains to the lack of approved pharmacological interventions for the treatment of nonalcoholic steatoh...
Autores principales: | Sookoian, Silvia, Pirola, Carlos J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478618/ https://www.ncbi.nlm.nih.gov/pubmed/31057294 http://dx.doi.org/10.3748/wjg.v25.i15.1783 |
Ejemplares similares
-
Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait
por: Pirola, Carlos J., et al.
Publicado: (2022) -
The lipidome in nonalcoholic fatty liver disease: actionable targets
por: Pirola, Carlos J., et al.
Publicado: (2021) -
Genetic predisposition in nonalcoholic fatty liver disease
por: Sookoian, Silvia, et al.
Publicado: (2017) -
Heat Shock Protein 27 is down-regulated in Ballooned Hepatocytes of Patients with Nonalcoholic Steatohepatitis (NASH)
por: Sookoian, Silvia, et al.
Publicado: (2016) -
Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology
por: Sookoian, Silvia, et al.
Publicado: (2020)